On September 13, 2024 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, reported four abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2024, which convenes in Barcelona, Spain, from September 13-17, 2024 (Press release, Tempus, SEP 13, 2024, View Source [SID1234646595]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"ESMO provides a great platform to share our recent research and advancements with the global oncology community, foster further collaboration, and drive forward the mission of improving patient outcomes," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "At Tempus, we are committed to leveraging AI and data to transform cancer care and research, and this is a great opportunity to showcase the impact of our innovative approaches to both."

This year, Tempus will share a few of its latest scientific and clinical research findings via one oral presentation and three poster presentations, including:

Oral Presentation (#CN13): Impact of AI Clinical Trial Program on Screening, Matching, and Enrollment of Patients Over 6 Months
Session Date & Time: Monday, September 16, 2024; 11:05-11:15 a.m. CEST
Location: Fira Barcelona Gran Via; Hall 7
Overview: In collaboration with Cleveland Clinic, Tempus’ TIME initiative streamlined large-scale patient screening and clinical trial matching, enhanced patient enrollment and access, and achieved an average of more than one consent per day over a six-month period. Utilizing AI for patient matching and accelerating trial activation is recommended to maximize clinical trial success.

Poster Presentation (#113P): The association of changes in circulating tumor fraction and in actionable variant allele frequencies with clinical outcomes in real world diverse cohort of advanced patients treated with Tyrosine Kinase inhibitors
Session Date & Time: Sunday, September 15, 2024; 9:00 a.m.-17:00 p.m. CEST
Location: Fira Barcelona Gran Via; Hall 6
Overview: This study evaluates the use of circulating tumor DNA (ctDNA) for monitoring treatment response in advanced solid tumor patients treated with tyrosine kinase inhibitors (TKIs). Using the Tempus xM ctDNA assay, patients were classified as molecular responders (MRs) or non-responders (nMRs) based on changes in ctDNA tumor fraction (TF). The majority of patients ( 69%) had targetable SNV/indels; 13 were MRs and 18 were nMRs. MRs had longer overall survival (no deaths during follow-up) than nMRs. Among patients with decreasing variant allele frequencies (VAF, n=21), patients that were MRs (n=12) had significantly longer survival compared to nMRs (n=9). The study suggests that ctDNA TF monitoring may be used clinically to monitor response to TKI therapy beyond targeted VAF monitoring alone and warrants further validation.

Poster Presentation (#79P): Comprehensive Genomic Profiling provides patients access to novel matched therapies in a diverse real world cohort of advanced lung cancer patients
Session Date & Time: Sunday, September 15, 2024; 9:00 a.m.-17:00 p.m. CEST
Location: Fira Barcelona Gran Via; Hall 6
Overview: This study assessed adherence with guideline-recommended targeted therapy recommendations and the time from genomic sequencing to the initiation of targeted treatment in a diverse, real-world dataset of advanced NSCLC patients. Findings show that most oncologists utilized comprehensive genomic profiling (CGP) to identify and treat patients with guideline-recommended, variant matched targeted therapy, with adherence rates varying according to the variant. Notably, even patients that received CGP results prior to FDA approval of novel therapies, received matched therapy once they were included in guidelines.

Poster Presentation (#580P): Impact of RAS and BRAFV600E mutations on tumor immune microenvironment and associated genomic alterations in patients with microsatellite instability (MSI) or DNA Mismatch Repair Deficient (dMMR) colorectal cancers
Session Date & Time: Monday, September 16, 2024; 9:00 a.m.-17:00 p.m. CEST
Location: Fira Barcelona Gran Via; Hall 6
Overview: This study aimed to understand the impact of RAS and BRAF mutations on prognosis and treatment effects in MSI/dMMR patients in both localized and metastatic settings. These data suggest that MSI/dMMR colorectal cancers (CRC) with RAS mutations are less immunogenic and exhibit a lower tumor inflammatory profile in the tumor immune microenvironment (TIME) compared to those with RAS wild-type (RASwt) or BRAF V600E mutations. Further analysis and validation are required to confirm these findings.